Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, MS, Non-interventional
Brief summary
Multiple Sclerosis (MS) is mainly known as a disease of young to middle adulthood but approximately 5% of all MS cases worldwide involve children that are younger than 16 years. The aim of care of children with Multiple Sclerosis is to prevent or at least to delay any neurological and cognitive impairment as well as progression of the disease as far as possible. Therefore, it is very crucial to diagnose the disease at an early stage as immunomodulatory treatments are available that can delay the progression of Multiple SclerosisTreatment with the immunomodulatory agent Betaferon® in children diagnosed with RRMS and being 12 years or older has been approved by the health authorities. The aim of this observational study is to obtain further data on the safety, tolerability, and effectiveness of Betaferon® under daily living conditions. As this is a non-interventional observational study, routine clinical practice is observed. The application of diagnostic measures and medications as well as physician visits follow the normal routine and is decided upon by the treating physician under recognition of the package insert.
Interventions
Patients under daily life treatment receiving Betaferon according to local product information.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
* Treatment naive children and adolescents of 12 to 16 years of age at inclusion with a diagnosis of RRMS according to revised McDonald or Poser criteria and decision taken by the investigator to treat with Betaferon. The local Betaferon product information must be considered.
Exclusion criteria
* Contraindications stated in the local Betaferon product information; warnings and precautions must be considered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of Betaferon in this patient population | Up 24 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to first relapse | Up to 24 months | — |
| Annualized relapse rate | Up to 24 months | — |
| Disability progression measured by the expanded disability status scale (EDSS) | Up to 24 months | — |
| Outcome on neurological function | Up to 24 months | e.g. IQ assessment using Standard Progressive Matrices (SPM) and Wechsler intelligence scale for children-fourth edition (WISCIV®), assessment of visual and motor integration using Beery VMI , and assessment of attention and concentration using d2 test. |
| Proportion of patients being relapse free | Up to 24 months | — |
| MRI measurements (if available) | Up to 24 months | e.g. number of new T2 lesions, number of new contrast enhancing lesions |
| MRI measurements and potential correlation with neuropsychological impairment | Up to 24 months | — |
| Laboratory outcomes | Up to 24 months | Laboratory examinations: hemoglobin, mean corpuscular volume, platelets, leukocytes, ALAT/GPT, ASAT/GOT, Alkaline phosphatase, and Gamma-GT |
| Fatigue assessed by Fatigue Severity Scale (FSS) | Up to 24 months | — |
Countries
Austria, Belgium, Finland, Germany, Israel, United Kingdom
Outcome results
None listed